Verigat2.5 mg

Verigat 2.5 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Recommended Dosage: The recommended starting dose of Verigat 2.5 mg is 2.5 mg orally once daily with food. Double the dose of Verigat 2.5 mg approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, Verigat 2.5 mg may be crushed and mixed with water immediately before administration.Pregnancy Testing in Females of Reproductive Potential: Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with Verigat 2.5 mg.Pediatric Use: Safety and effectiveness of Verigat 2.5 mg have not been established in pediatric patients.

Other Soluble Guanylate Cyclase Stimulators: Verigat 2.5 mg is contraindicated in patients with concomitant use of another soluble guanylate cyclase (sGC) stimulator.PDE-5 Inhibitors: Concomitant use of Verigat 2.5 mg with PDE-5 inhibitors is not recommended because of the potential for hypotension.

Verigat 2.5 mg is contraindicated in patients with concomitant use of another soluble guanylate cyclase (sGC) stimulator. Verigat 2.5 mg is contraindicated in pregnancy.

Based on data from animal reproduction studies, Verigat 2.5 mg may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with Verigat 2.5 mg and for at least one month after the final dose.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Stimulator of soluble guanylate cyclase

Verigat 2.5 mg is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, and cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, Verigat 2.5 mg augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.

Based on data from animal reproduction studies, Verigat 2.5 mg may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy. There are no data on the presence of Verigat 2.5 mg in human milk, the effects on the breastfed infant, or the effects on milk production. Verigat 2.5 mg is present in the milk of lactating rats and it is likely that Verigat 2.5 mg or its metabolites are present in human milk. Because of the potential for serious adverse reactions in breastfed infants from Verigat 2.5 mg, advise women not to breastfeed during treatment with Verigat 2.5 mg.